Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 2
2014 1
2015 2
2016 2
2018 1
2019 1
2020 2
2021 2
2022 6
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating Epstein-Barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
Shen EY, Hung TM, Tsan DL, Cheng NM, Kang CJ, Huang SF, Hsu CL, Lin CY, Wang HM, Hsieh JC, Cheng AJ, Fan KH, Chang JT. Shen EY, et al. Among authors: tsan dl. Radiother Oncol. 2022 Dec;177:1-8. doi: 10.1016/j.radonc.2022.05.004. Epub 2022 May 11. Radiother Oncol. 2022. PMID: 35568282
Maintenance of multi-domain neurocognitive functions in patients with newly-diagnosed primary CNS lymphoma after primary cranial radiotherapy combined with methotrexate-based chemotherapy: A preliminary case-series study.
Lin SY, Chuang CC, Tsan DL, Hung YS, Fu CJ, Shen YL, Chiang YY, Huang YC, Lu YJ, Yang CC. Lin SY, et al. Among authors: tsan dl. Appl Neuropsychol Adult. 2022 May-Jun;29(3):432-441. doi: 10.1080/23279095.2020.1749630. Epub 2020 Apr 17. Appl Neuropsychol Adult. 2022. PMID: 32301346
Adjuvant Chemoradiotherapy Associated with Improved Overall Survival in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
Yap WK, Shih MC, Chang YC, Lin CH, Huang SM, Tsai TY, Chang CF, Hsu CC, Tseng CK, Chen MF, Tsan DL, Liau CT, Hou MM, Chao YK, Chiu CH, Hung TM. Yap WK, et al. Among authors: tsan dl. Biomedicines. 2022 Nov 21;10(11):2989. doi: 10.3390/biomedicines10112989. Biomedicines. 2022. PMID: 36428557 Free PMC article.
Oncological Outcomes After Hippocampus-Sparing Whole-Brain Radiotherapy in Cancer Patients With Newly Diagnosed Brain Oligometastases: A Single-Arm Prospective Observational Cohort Study in Taiwan.
Lin SY, Tsan DL, Chuang CC, Yang CC, Pai PC, Wang CL, Wu YM, Lee CC, Lin CH, Wei KC, Chou WC. Lin SY, et al. Among authors: tsan dl. Front Oncol. 2022 Jan 12;11:784635. doi: 10.3389/fonc.2021.784635. eCollection 2021. Front Oncol. 2022. PMID: 35096584 Free PMC article.
Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, Kuan FC, Hsieh CH, Kuo YC, Sheng TW, Chang CF, Yu SM, Huang WK, Lin YC, Tsan DL, Yu KJ, Lin PH, Chen HY, Chang YH, Pang ST, Chuang CK, Lai EC. Chen HK, et al. Among authors: tsan dl. Int J Cancer. 2023 Mar 15;152(6):1191-1201. doi: 10.1002/ijc.34348. Epub 2022 Dec 9. Int J Cancer. 2023. PMID: 36346116 Free article.
19 results